The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men
Overview
Authors
Affiliations
Background: Athletes often take androgenic steroids in an attempt to increase their strength. The efficacy of these substances for this purpose is unsubstantiated, however.
Methods: We randomly assigned 43 normal men to one of four groups: placebo with no exercise; testosterone with no exercise; placebo plus exercise; and testosterone plus exercise. The men received injections of 600 mg of testosterone enanthate or placebo weekly for 10 weeks. The men in the exercise groups performed standardized weight-lifting exercises three times weekly. Before and after the treatment period, fat-free mass was determined by underwater weighing, muscle size was measured by magnetic resonance imaging, and the strength of the arms and legs was assessed by bench-press and squatting exercises, respectively.
Results: Among the men in the no-exercise groups, those given testosterone had greater increases than those given placebo in muscle size in their arms (mean [+/-SE] change in triceps area, 424 +/- 104 vs. -81 +/- 109 square millimeters; P < 0.05) and legs (change in quadriceps area, 607 +/- 123 vs. -131 +/- 111 square millimeters; P < 0.05) and greater increases in strength in the bench-press (9 +/- 4 vs. -1 +/- 1 kg, P < 0.05) and squatting exercises (16 +/- 4 vs. 3 +/- 1 kg, P < 0.05). The men assigned to testosterone and exercise had greater increases in fat-free mass (6.1 +/- 0.6 kg) and muscle size (triceps area, 501 +/- 104 square millimeters; quadriceps area, 1174 +/- 91 square millimeters) than those assigned to either no-exercise group, and greater increases in muscle strength (bench-press strength, 22 +/- 2 kg; squatting-exercise capacity, 38 +/- 4 kg) than either no-exercise group. Neither mood nor behavior was altered in any group.
Conclusions: Supraphysiologic doses of testosterone, especially when combined with strength training, increase fat-free mass and muscle size and strength in normal men.
Age- and sex-related development of osteosarcopenia in the aging rodent model.
Gallo-Soljancic P, De Stefano M, Lucas-Ochoa A, Sanchez-Rodrigo C, Cuemca-Bermejo L, Gonzalez-Cuello A Front Aging. 2025; 6:1486670.
PMID: 40018266 PMC: 11865034. DOI: 10.3389/fragi.2025.1486670.
The androgen clock is an epigenetic predictor of long-term male hormone exposure.
Sugrue V, Prescott M, Glendining K, Bond D, Horvath S, Anderson G Proc Natl Acad Sci U S A. 2025; 122(3):e2420087121.
PMID: 39805019 PMC: 11760496. DOI: 10.1073/pnas.2420087121.
Kutscher E, Arshed A, Greene R, Kladney M Harm Reduct J. 2024; 21(1):196.
PMID: 39523302 PMC: 11552109. DOI: 10.1186/s12954-024-01121-8.
Nokoff N, Nemkov T, Bothwell S, Cree M, Fuller K, Keller A J Appl Physiol (1985). 2024; 137(5):1470-1483.
PMID: 39417821 PMC: 11573275. DOI: 10.1152/japplphysiol.00629.2024.
Sakai H, Uno H, Yamakawa H, Tanaka K, Ikedo A, Uezumi A Proc Natl Acad Sci U S A. 2024; 121(39):e2407768121.
PMID: 39292748 PMC: 11441553. DOI: 10.1073/pnas.2407768121.